Quest Diagnostics Incorporated has announced the launch of a novel blood test utilizing advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with multiple myeloma. The Quest Flow Cytometry MRD for Myeloma test offers sensitivity comparable to next-generation sequencing $(NGS)$ techniques but uses noninvasive blood specimens instead of bone marrow aspirates. The test features five-day specimen stability, exceeding the stability of conventional flow cytometry methods, and does not require a baseline aspirate sample for monitoring. The test was introduced at the recent American Society of Hematology $(ASH)$ Annual Meeting and Exposition, where the company presented information to the medical community. Quest Diagnostics expects the test to support both clinical care and response monitoring in clinical trials for multiple myeloma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: NY75299) on February 02, 2026, and is solely responsible for the information contained therein.